Title: Health Korea News– Green Cross, signs of jackpot in the US. Publication: Health Korea
News
Publication: Health Korea News / Ji Hye Kim
Date: 01 December 2011
Summary
Green Cross
reported the US FDA approved the clinical trial of new anticoagulant
‘GCC4401C”. ‘GCC4401C’ is
a FactorXa Inhibitor blocks 10 major factors of thrombus to remove blood clots
in vessels. In 2009,
Green Cross bought a candidate substance for anticoagulant ‘GCC4401C’ from
LegoChem Bioscience and in the same year, the state Ministry of Knowledge
Economy selected the drug as a government funded bio-medical project.
To view the full article
(in Korean), click here ▶
About
LegoChem Biosciences
LegoChem
Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to
discovering, developing, and commercializing innovative medicines by leveraging
our chemistry expertise to make conventional biologics targeted and more potent
for the benefit of patients with diseases of high unmet medical needs. We are
advancing sustainable pipelines in therapeutic areas in antibiotics,
anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug
conjugate (PDC).
|
|
IP : 106.243.208.*** 
|
